China-Coronavirus/Vaccine Trial
Beijing, China - Oct 18, 2020 (CCTV - No access Chinese mainland)
1. Various of screenshot showing China's COVID-19 vaccine study in Lancet Infectious Diseases journal
FILE: China - Exact Date and Location Unknown (CCTV - No access Chinese mainland)
2. Various of medical workers conducting vaccine research in lab
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
3. Various of researchers conducting experiment
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
4. Various of vaccine production line
FILE: Wuhan City, Hubei Province, central China - March 16, 2020 (CCTV - No access Chinese mainland)
5. Bottles of vaccine
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
6. Various of vaccine production line, researchers at production line
FILE: Wuhan City, Hubei Province, central China - May 2020 (CCTV - No access Chinese mainland)
7. Medical worker injecting vaccine
8. Various of volunteers receiving vaccine injections
A COVID-19 vaccine candidate developed by China based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomized clinical trial published Thursday in The Lancet Infectious Diseases journal.
The report said that from April 29 to July 30 this year, researchers from institutions including the Beijing Institute of Biological Products carried out related clinical trials in China, involving more than 600 healthy participants aged between 18 and 80 years old.
The latest study found that antibody responses were induced in all recipients within 42 days, and no serious adverse reaction occurred.
The research team stated that the trial at this stage is mainly to evaluate the immune response and vaccine safety, which has not been possible to confirm whether the vaccine is sufficient to protect people from SARS-CoV-2 infection. Further analysis and trials are needed to evaluate it. The preliminary trial result also provides very useful information for phase 3 clinical trials.
According to statistics from the World Health Organization, there are currently more than 40 COVID-19 vaccines in clinical trials worldwide, including vaccines with different types of technical routes, some of which have demonstrated safety in early clinical trials and can induce immune responses in human beings.
China-Coronavirus/Vaccine Trial
Dateline : Oct 18, 2020/File
Location : China
Duration : 1'06
Beijing, China - Oct 18, 2020 (CCTV - No access Chinese mainland)
1. Various of screenshot showing China's COVID-19 vaccine study in Lancet Infectious Diseases journal
FILE: China - Exact Date and Location Unknown (CCTV - No access Chinese mainland)
2. Various of medical workers conducting vaccine research in lab
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
3. Various of researchers conducting experiment
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
4. Various of vaccine production line
FILE: Wuhan City, Hubei Province, central China - March 16, 2020 (CCTV - No access Chinese mainland)
5. Bottles of vaccine
FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
6. Various of vaccine production line, researchers at production line
FILE: Wuhan City, Hubei Province, central China - May 2020 (CCTV - No access Chinese mainland)
7. Medical worker injecting vaccine
8. Various of volunteers receiving vaccine injections
A COVID-19 vaccine candidate developed by China based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomized clinical trial published Thursday in The Lancet Infectious Diseases journal.
The report said that from April 29 to July 30 this year, researchers from institutions including the Beijing Institute of Biological Products carried out related clinical trials in China, involving more than 600 healthy participants aged between 18 and 80 years old.
The latest study found that antibody responses were induced in all recipients within 42 days, and no serious adverse reaction occurred.
The research team stated that the trial at this stage is mainly to evaluate the immune response and vaccine safety, which has not been possible to confirm whether the vaccine is sufficient to protect people from SARS-CoV-2 infection. Further analysis and trials are needed to evaluate it. The preliminary trial result also provides very useful information for phase 3 clinical trials.
According to statistics from the World Health Organization, there are currently more than 40 COVID-19 vaccines in clinical trials worldwide, including vaccines with different types of technical routes, some of which have demonstrated safety in early clinical trials and can induce immune responses in human beings.
ID : 8161993
Published : 2020-10-18 03:09
Last Modified : 2020-10-18 17:03:00
Source : China Central Television (CCTV),China Global Television Network (CGTN)
Restrictions : No access Chinese mainland
More